Antimalarial Bioavailability and Disposition of Artesunate in Acute Falciparum Malaria

ABSTRACT The pharmacokinetic properties of oral and intravenous artesunate (2 mg/kg of body weight) were studied in 19 adult patients with acute uncomplicated Plasmodium falciparum malaria by using a randomized crossover design. A sensitive bioassay was used to measure the antimalarial activity in plasma which results from artesunate and its principal metabolite, dihydroartemisinin. The oral study was repeated with 15 patients during convalescence. The mean absolute oral bioavailability of the antimalarial agent in patients with acute malaria was 61% (95% confidence interval [CI], 52 to 70%). The absorption and elimination of oral artesunate were rapid, with a mean elimination half-life of antimalarial activity of 43 min (95% CI, 33 to 53 min). Following oral administration to patients with acute falciparum malaria, peak antimalarial activity in plasma and the area under the plasma concentration-time curve were approximately double those during convalescence and the apparent volume of distribution and clearance were approximately half those during convalescence (P ≤ 0.005). Acute malaria is associated with a significant reduction in the clearance of artesunate-associated antimalarial activity.

[1]  B. K. Park,et al.  The rat biliary metabolites of dihydroartemisinin, an antimalarial endoperoxide. , 1997, Drug metabolism and disposition: the biological fate of chemicals.

[2]  M. Molyneux,et al.  Reduced hepatic blood flow and intestinal malabsorption in severe falciparum malaria. , 1989, The American journal of tropical medicine and hygiene.

[3]  D. Skanchy,et al.  Metabolism of artelinic acid to dihydroqinqhaosu by human liver cytochrome P4503A. , 1999, Xenobiotica; the fate of foreign compounds in biological systems.

[4]  D. Kyle,et al.  Comparative bioavailability of oral, rectal, and intramuscular artemether in healthy subjects: use of simultaneous measurement by high performance liquid chromatography and bioassay. , 1996, British journal of clinical pharmacology.

[5]  P. D. de Vries,et al.  Declining Concentrations of Dihydroartemisinin in Plasma during 5-Day Oral Treatment with Artesunate for Falciparum Malaria , 1999, Antimicrobial Agents and Chemotherapy.

[6]  T. Q. Binh,et al.  A pharmacokinetic and pharmacodynamic study of intravenous vs oral artesunate in uncomplicated falciparum malaria. , 1998, British journal of clinical pharmacology.

[7]  B. K. Park,et al.  Assessment of the effect of malaria infection on hepatic clearance of dihydroartemisinin using rat liver perfusions and microsomes , 1998, British journal of pharmacology.

[8]  M. Mordi,et al.  Simultaneous determination of artesunic acid and dihydroartemisinin in blood plasma by high-performance liquid chromatography for application in clinical pharmacological studies. , 1997, Journal of chromatography. B, Biomedical sciences and applications.

[9]  D. Kyle,et al.  Pharmacokinetics of oral artesunate in children with moderately severe Plasmodium falciparum malaria. , 1997, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[10]  H. Webster,et al.  Arteether: risks of two-week administration in Macaca mulatta. , 1997, The American journal of tropical medicine and hygiene.

[11]  K. Silamut,et al.  Alpha 1-acid glycoprotein (orosomucoid) and plasma protein binding of quinine in falciparum malaria. , 1991, British journal of clinical pharmacology.

[12]  N. White,et al.  Treatment of multidrug-resistant Plasmodium falciparum malaria with 3-day artesunate-mefloquine combination. , 1994, The Journal of infectious diseases.

[13]  P. Manson-Bahr,et al.  Manson's Tropical Diseases , 1929 .

[14]  D. Kyle,et al.  A study of the factors affecting the metabolic clearance of quinine in malaria , 1997, European Journal of Clinical Pharmacology.

[15]  N. White,et al.  Antimalarial pharmacokinetics and treatment regimens. , 1992, British journal of clinical pharmacology.

[16]  S. Yang,et al.  CLINICAL PHARMACOKINETICS OF A NEW EFFECTIVE ANTIMALARIAL ARTESUNATE, A QINGHAOSU DERIVATIVE , 1985 .

[17]  N. White,et al.  Assessment of the pharmacodynamic properties of antimalarial drugs in vivo , 1997, Antimicrobial agents and chemotherapy.

[18]  William F. Hughes,et al.  Manson's Tropical Diseases , 1914, The Indian Medical Gazette.

[19]  N. White,et al.  Clinical Pharmacokinetics and Pharmacodynamics of Artemether-Lumefantrine , 1999 .

[20]  K. Silamut,et al.  A simple method for assessing quinine pre-treatment in acute malaria. , 1995, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[21]  A. Buck,et al.  Efficient assessment of filariasis endemicity by screening for filarial antigenaemia in a sentinel population. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[22]  M R Prabha Adhikari,et al.  Severe and complicated malaria. , 2002, Indian journal of medical sciences.

[23]  L. Cong,et al.  Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[24]  J. Karbwang,et al.  Pharmacokinetic and bioequivalence evaluation of two generic formulations of oral artesunate , 1998, European Journal of Clinical Pharmacology.

[25]  A. Fitton,et al.  Artesunate. A review of its pharmacology and therapeutic efficacy in the treatment of malaria. , 1995, Drugs.

[26]  N. White,et al.  Clinical pharmacokinetics and pharmacodynamics of artemisinin and derivatives. , 1994, Transactions of the Royal Society of Tropical Medicine and Hygiene.

[27]  S. Powell,et al.  A pharmacokinetic and pharmacodynamic study of artesunate for vivax malaria. , 1998, The American journal of tropical medicine and hygiene.